Sarepta Therapeutics: Drug Development and Licensing in Six Frameworks

How do scientific partnerships, clinical delivery and reimbursement pathways connect to sustainable value creation?

The Sarepta Therapeutics Business Model Canvas links the nine building blocks: customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partnerships and cost structure. It is particularly useful for a genetic-medicine business where research capabilities, licensing relationships, academic collaborations, clinical evidence and access infrastructure must work together before value can be realized. The lens helps connect patient need with the operating and economic model behind a therapy portfolio.

• Value pathway. Trace how rare-disease treatment needs may connect with specialist care, patient support and reimbursement decision-making.
• Collaboration model. Consider how research institutions, technology partners and external capabilities can support key activities and resources.
• Connected mapping. Populate the Excel canvas block by block and use the Word analysis to explain dependencies between partnerships, costs and revenue logic.

How can a rare-disease therapy portfolio be assessed through product, pricing, access and communication choices?

The Sarepta Therapeutics Marketing Mix considers Product, Price, Place and Promotion in a regulated biopharmaceutical setting. Product analysis can examine clinical profile, treatment burden and evidence needs; price analysis can consider value communication, reimbursement and affordability questions. Place focuses on routes through specialist prescribers, treatment centres and distribution arrangements, while promotion addresses compliant scientific and disease education for appropriate professional and patient audiences. Together, the four Ps help organize commercial questions without inventing prices, campaigns or channel shares.

• Therapy proposition. Assess how treatment differentiation and patient eligibility may affect the value proposition presented to healthcare stakeholders.
• Access design. Compare potential friction points across payer review, specialist referral, treatment delivery and patient support.
• Commercial planning. Use the Excel structure to compare the four Ps and use the Word analysis to retain context behind each choice.

How can Sarepta's internal capabilities and constraints be considered alongside changing rare-disease market conditions?

A Sarepta Therapeutics SWOT analysis separates internal Strengths and Weaknesses from external Opportunities and Threats. It provides a useful synthesis for a company operating where scientific expertise, partnership networks, clinical development execution and regulatory knowledge may be important internal considerations. Opportunities and threats, by contrast, can arise from technology evolution, access conditions, policy uncertainty and competitive activity outside the company’s direct control. The framework helps keep these categories distinct before strategic implications are discussed.

• Internal diagnosis. Consider capabilities, resource demands, execution dependencies and organizational constraints without treating possible themes as proven findings.
• External fit. Relate market openings and sector threats to the conditions identified through the Five Forces and PESTLE lenses.
• Decision synthesis. Use the Excel grid to prioritize discussion items, then use the Word analysis to develop evidence-based strategic questions around them.